NASDAQ:PRQR - ProQR Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$17.15 -0.84 (-4.67 %)
(As of 12/10/2018 01:32 PM ET)
Previous Close$17.99
Today's Range$17.02 - $18.38
52-Week Range$2.75 - $24.00
Volume3,281 shs
Average Volume323,401 shs
Market Capitalization$696.49 million
P/E Ratio-9.26
Dividend YieldN/A
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. Its lead product candidates include eluforsen, a RNA-based oligonucleotide used for the treatment of cystic fibrosis; QR-110, an oligonucleotide that is designed to treat Leber's congenital amaurosis; QR-313, a dermatology candidate for the treatment of epidermolysis bullosa; and QR-421a and QR-411 to treat type 2A Usher syndrome. It is also developing QRX-1011, a single-stranded oligonucleotide for Stargards disease; QRX-704, an oligonucleotide for the treatment of Huntington's disease; and QRX-504 to treat Fuchs' endothelial corneal dystrophy type 3, as well as AT-010, a program for hereditary cerebral hemorrhage with amyloidosis of the Dutch type. The company has a research collaboration agreement with Galapagos N.V. to apply Axiomer, a RNA Editing Technology Platform for various fibrosis targets; and a collaboration agreement with EB Research Partnership and EB Medical Research Foundation to develop QR-313 for patients with dystrophic epidermolysis bullosa. ProQR Therapeutics N.V. was founded in 2012 and is headquartered in Leiden, the Netherlands.

Receive PRQR News and Ratings via Email

Sign-up to receive the latest news and ratings for PRQR and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Current SymbolNASDAQ:PRQR
Previous Symbol


Debt-to-Equity Ratio0.06
Current Ratio11.39
Quick Ratio11.39


Trailing P/E Ratio-9.26
Forward P/E Ratio-13.83
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book Value$1.39 per share
Price / Book12.34


EPS (Most Recent Fiscal Year)($1.94)
Net Income$-49,320,000.00
Net MarginsN/A
Return on Equity-74.20%
Return on Assets-57.03%


Outstanding Shares38,720,000
Market Cap$696.49 million

ProQR Therapeutics (NASDAQ:PRQR) Frequently Asked Questions

What is ProQR Therapeutics' stock symbol?

ProQR Therapeutics trades on the NASDAQ under the ticker symbol "PRQR."

How were ProQR Therapeutics' earnings last quarter?

ProQR Therapeutics NV (NASDAQ:PRQR) posted its quarterly earnings data on Wednesday, November, 7th. The biopharmaceutical company reported ($0.21) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.31) by $0.10. View ProQR Therapeutics' Earnings History.

When is ProQR Therapeutics' next earnings date?

ProQR Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, February 27th 2019. View Earnings Estimates for ProQR Therapeutics.

What price target have analysts set for PRQR?

5 analysts have issued twelve-month price targets for ProQR Therapeutics' shares. Their forecasts range from $9.00 to $40.00. On average, they expect ProQR Therapeutics' share price to reach $27.20 in the next twelve months. This suggests a possible upside of 58.4% from the stock's current price. View Analyst Price Targets for ProQR Therapeutics.

What is the consensus analysts' recommendation for ProQR Therapeutics?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ProQR Therapeutics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ProQR Therapeutics.

What are Wall Street analysts saying about ProQR Therapeutics stock?

Here are some recent quotes from research analysts about ProQR Therapeutics stock:
  • 1. Cantor Fitzgerald analysts commented, ". Initiating at OW and $40 12-month PT. ProQR is a European RNA-based platform technology company focused on developing therapeutics for inherited blindness. Although shares are up close to 500% YTD (vs. XBI down 9%) after positive proof of concept in first ophthalmology drug QR-110, we think this could be just the beginning of a major turning point for the company’s platform. In September, ProQR established the first proof of concept for its RNA platform in inherited ophthalmology with lead asset QR-110. We think QR-110 could be just the tip of the iceberg in terms of PRQR’s platform potential in inherited forms of blindness. In this report, we are focused on the company’s next clinical program in Usher’s Syndrome which represents a larger opportunity than QR-110 (we estimate $1.1B peak vs. $300M peak) and is guided to have clinical data in 2019." (11/13/2018)
  • 2. According to Zacks Investment Research, "ProQR Therapeutics B.V. is a biotech company. It is engaged in the discovery and development of RNA-based therapeutics for the treatment of severe genetic disorders, with an initial focus on Cystic Fibrosis (CF). The Company's lead product candidate includes QR-010, a RNA-based oligonucleotide for the treatment of cystic fibrosis. ProQR Therapeutics B.V. is headquartered in Leiden, the Netherlands. " (11/7/2018)
  • 3. HC Wainwright analysts commented, "Our price target of $20/share is based on an equally-weighted composite of: (a) $18.0/ share, as a 25x multiple of taxed and diluted $9.92 discounted back to FY18 at 30% (in line with the expected PE multiple and discount rate of an early development-stage biotechnology company); and (b) an NPV of $21.9/ share (discounted cash flow analysis using a 18% discount rate and 2.0% growth rate, in line with the expected discount and growth parameters of an early development-stage biotechnology company)." (10/30/2018)

Has ProQR Therapeutics been receiving favorable news coverage?

Media stories about PRQR stock have been trending very positive this week, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. ProQR Therapeutics earned a daily sentiment score of 3.9 on InfoTrie's scale. They also gave media stories about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the stock's share price in the immediate future.

Are investors shorting ProQR Therapeutics?

ProQR Therapeutics saw a increase in short interest during the month of October. As of October 31st, there was short interest totalling 985,408 shares, an increase of 60.6% from the October 15th total of 613,551 shares. Based on an average daily trading volume, of 254,800 shares, the short-interest ratio is presently 3.9 days. Currently, 3.7% of the company's shares are sold short. View ProQR Therapeutics' Current Options Chain.

Who are some of ProQR Therapeutics' key competitors?

Who are ProQR Therapeutics' key executives?

ProQR Therapeutics' management team includes the folowing people:
  • Mr. Daniel A. de Boer, CEO & Member of Management Board (Age 35)
  • Mr. Rene K. Beukema, Chief Corp. Devel. Officer, Gen. Counsel, Sec. & Member of Management Board (Age 54)
  • Ms. Smital Shah, Chief Financial Officer (Age 42)
  • Mr. Joost Clement, Director of HR
  • Mr. Bart Klein, Sr. VP of Intellectual Property

Who are ProQR Therapeutics' major shareholders?

ProQR Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Jennison Associates LLC (7.78%), Redmile Group LLC (3.75%), Artal Group S.A. (3.37%), FMR LLC (2.20%), Perceptive Advisors LLC (1.97%) and Morgan Stanley (1.05%).

Which institutional investors are selling ProQR Therapeutics stock?

PRQR stock was sold by a variety of institutional investors in the last quarter, including Artal Group S.A., Sphera Funds Management LTD., Essex Investment Management Co. LLC, Franklin Street Advisors Inc. NC, Credit Suisse AG and Opus Point Partners Management LLC.

Which institutional investors are buying ProQR Therapeutics stock?

PRQR stock was bought by a variety of institutional investors in the last quarter, including Redmile Group LLC, Perceptive Advisors LLC, FMR LLC, Morgan Stanley, Monashee Investment Management LLC, Nexthera Capital LP and Jennison Associates LLC.

How do I buy shares of ProQR Therapeutics?

Shares of PRQR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ProQR Therapeutics' stock price today?

One share of PRQR stock can currently be purchased for approximately $17.17.

How big of a company is ProQR Therapeutics?

ProQR Therapeutics has a market capitalization of $696.49 million. The biopharmaceutical company earns $-49,320,000.00 in net income (profit) each year or ($1.94) on an earnings per share basis. ProQR Therapeutics employs 130 workers across the globe.

What is ProQR Therapeutics' official website?

The official website for ProQR Therapeutics is

How can I contact ProQR Therapeutics?

ProQR Therapeutics' mailing address is Zernikedreef 9, Leiden P7, 2333 CK. The biopharmaceutical company can be reached via phone at 31-88-166-7000 or via email at [email protected]

MarketBeat Community Rating for ProQR Therapeutics (NASDAQ PRQR)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  179 (Vote Outperform)
Underperform Votes:  186 (Vote Underperform)
Total Votes:  365
MarketBeat's community ratings are surveys of what our community members think about ProQR Therapeutics and other stocks. Vote "Outperform" if you believe PRQR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PRQR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/10/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel